← Back to Search

Learning Algorithm

Sensor augmented MDI therapy plus mobile application for Type 1 Diabetes

N/A
Waitlist Available
Led By Michael Tsoukas, MD
Research Sponsored by McGill University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Signed and dated informed consent form
Females and males ≥ 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up post-intervention, approximately 4 months
Awards & highlights

Study Summary

This trial showed that the learning algorithm was able to suggest appropriate basal and bolus dose recommendations for high-fat meals and exercise for people with type 1 diabetes.

Eligible Conditions
  • Type 1 Diabetes

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~post-intervention, approximately 4 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and post-intervention, approximately 4 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Comparison of 5 hours postprandial incremental area under the curve of glucose (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations
Comparison of 5 hours postprandial percentage of time below 3.9 mmol/L (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations
Secondary outcome measures
Comparison of 24 hours coefficient of variance of glucose levels (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations
Comparison of 24 hours incremental area under the curve of glucose levels (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations
Comparison of 24 hours mean glucose level (for high-fat meals and/or postprandial exercise) of the last month algorithm recommendations with the first month recommendations
+23 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Sensor augmented MDI therapy plus mobile application with reinforcement learning algorithmExperimental Treatment1 Intervention
Participants with type 1 diabetes will undergo sensor-augmented MDI therapy for 4 months using a freestyle libre glucose sensor (Abbott Diabetes Care) and a mobile application integrated with the reinforcement learning algorithm.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sensor augmented MDI therapy plus mobile application
2021
N/A
~20

Find a Location

Who is running the clinical trial?

McGill UniversityLead Sponsor
394 Previous Clinical Trials
998,366 Total Patients Enrolled
Ahmad Haidar, PhDStudy ChairMcGill University Health Centre/Research Institute of the McGill University Health Centre
1 Previous Clinical Trials
25 Total Patients Enrolled
Michael Tsoukas, MDPrincipal InvestigatorMcGill University Health Centre/Research Institute of the McGill University Health Centre
4 Previous Clinical Trials
135 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Learning Algorithm for MDI Individuals With Type 1 Diabetes to Adjust Recommendations for High Fat Meals and Exercise Management
2021. "A Learning Algorithm for MDI Individuals With Type 1 Diabetes to Adjust Recommendations for High Fat Meals and Exercise Management". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05041621.
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top